clinical trial · NCT03594422
A Study of HQP1351 in Patients With GIST or Other Solid Tumors
Gastrointestinal Stromal Tumor (GIST)Solid Tumor, AdultHQP1351
brief summary
This study is a Multi-center, Open-label Phase 1 Study to Determine the Recommend Phase 2 Dose (RP2D) and Evaluate PK/PD and preliminary Efficacy of HQP1351 in Patients With GIST or Other Solid Tumors.
started
Jul 11, 2018
primary completion
Dec 1, 2027
completion
Dec 1, 2028
last updated
Apr 9, 2026
detailed description
The primary objective of this phase 1 study is to determine the RP2D of HQP1351 in patients with GIST or other solid tumors. The secondary objective is to assess the safety, tolerability, PK and preliminary anti-tumor activities of HQP1351 in Patients With GIST or Other Solid Tumors.
official title
A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Oral HQP1351 in Patients With GIST or Other Solid Tumors.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol